Nestle CEO Sees Weight-Loss Drugs Lifting Vitamin Sales
- Schneider downplays risk of GLP-1 treatments to Nestle sales
- Vitamins, supplements to see higher growth rates from 2024
This article is for subscribers only.
Nestle SA Chief Executive Officer Mark Schneider said the company’s nutritional products will benefit from a boom in weight-loss drugs, as consumers turn to offerings like Orgain protein shakes and Solgar vitamins.
The success of medicines known as GLP-1s for obesity has rippled beyond the pharmaceutical market, raising worries among investors that their effect on users’ appetites will curb demand for products like KitKat wafers.